Cantor Fitzgerald Reiterates Overweight on Celldex Therapeutics, Maintains $67 Price Target
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Kristen Kluska has reiterated an Overweight rating on Celldex Therapeutics (NASDAQ:CLDX) and maintained a price target of $67. This reaffirmation highlights the firm's positive outlook on the company's stock.
March 22, 2024 | 5:51 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cantor Fitzgerald analyst Kristen Kluska reaffirmed an Overweight rating on Celldex Therapeutics with a $67 price target, indicating a positive outlook.
The reiteration of an Overweight rating and a high price target by a reputable analyst like Kristen Kluska suggests a strong confidence in Celldex Therapeutics' future performance. This could lead to increased investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100